pinocembrin has been researched along with myricetin in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Chang, CJ; Geahlen, RL | 1 |
Habtemariam, S | 1 |
Bremer, R; Holder, S; Lilly, MB; Neidigh, JW; Tabrizizad, M; Zemskova, M; Zhang, C | 1 |
Brown, ML; Holder, S; Lilly, M | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Bicknell, KA; Farrimond, JA; Putnam, SE; Swioklo, S; Watson, KA; Williamson, EM | 1 |
Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
Murata, RM; Pardi, V; Pasetto, S | 1 |
Belduz, AO; Guler, HI; Kolayli, S; Tatar, G; Yildiz, O | 1 |
Kang, Y; Kim, BG; Kim, S; Lee, Y; Yoon, Y | 1 |
2 review(s) available for pinocembrin and myricetin
Article | Year |
---|---|
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Protein-Tyrosine Kinases | 1992 |
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |
8 other study(ies) available for pinocembrin and myricetin
Article | Year |
---|---|
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
Topics: Animals; Apoptosis; Drug Synergism; Flavonoids; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Topics: Chromones; Crystallography, X-Ray; Flavones; Flavonoids; Humans; Male; Phenotype; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Proto-Oncogene Proteins c-pim-1; Sensitivity and Specificity; Substrate Specificity | 2007 |
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Topics: Binding Sites; Computer Simulation; Databases, Factual; Drug Design; Enzyme Inhibitors; Flavonoids; Humans; Ligands; Models, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins c-pim-1; Quantitative Structure-Activity Relationship; Static Electricity; Stereoisomerism | 2007 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
Topics: Cell Differentiation; Flavonoids; Humans; Mesenchymal Stem Cells; Molecular Structure; Osteogenesis; Signal Transduction; Structure-Activity Relationship | 2015 |
Anti-HIV-1 activity of flavonoid myricetin on HIV-1 infection in a dual-chamber in vitro model.
Topics: Anti-HIV Agents; Female; Flavanones; Flavonoids; Genitalia, Female; HeLa Cells; HIV Infections; HIV-1; Humans; Models, Biological; Quercetin | 2014 |
Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study.
Topics: Angiotensin-Converting Enzyme 2; Animals; Bees; Caffeic Acids; COVID-19 Drug Treatment; Flavanones; Flavonoids; Hesperidin; Humans; Luteolin; Molecular Docking Simulation; Phenylethyl Alcohol; Plant Extracts; Propolis; Quercetin; Rutin | 2021 |
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Binding Sites; Flavones; Flavonoids; Flavonols; Liposomes; Molecular Docking Simulation; Phosphatidylinositol Phosphates; Pleckstrin Homology Domains; Protein Binding; Quantitative Structure-Activity Relationship | 2017 |